The Download: Europe’s heat wave hits the grid, and IBM’s chip targets Moore’s Law

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

Europe’s extreme heat is shutting down power plants

Europe is in the middle of a record-breaking heat wave, and the grid is being pushed to its limits as people turn to fans and air-conditioning to try to stay cool. But some power plants won’t be online to help handle the load.

The main source of stress is increased demand, largely driven by cooling. And the challenges are only expected to worsen as climate change brings more frequent and intense heat waves.

Find out how rising temperatures are stretching power supplies—and how utilities can adapt.

—Casey Crownhart

What Europe’s heat wave means for the power grid

Grid planning in the age of climate change generally means that we need a lot more supply, and quickly. But one interesting facet to this challenge is that in some places, seasonal patterns are shifting, compounding the difficulty of meeting demand. 

Europe has historically seen its grid peak in the winter when electric heating is widespread. So some planned outages happen in the spring and into the summer, which is affecting the supply right now. But a growing need for air-conditioning will alter the balance.

Read the full story on how climate change is reshaping electricity demand.

—Casey Crownhart

This story is from The Spark, our weekly newsletter giving you the inside track on all things climate. Sign up to receive it in your inbox every Wednesday.

IBM unveils chip technology that could help extend Moore’s Law another decade

IBM has built a new prototype chip with around 100 billion transistors on an area the size of a fingernail. That’s twice the density of the company’s previous state-of-the-art technology announced in 2021. And the design could pave the way for faster and more energy-efficient computers for years to come.

In the last fifteen years, transistors have been shrunk close to their limits. They can’t get smaller without their function deteriorating. IBM’s new chip resolves this with an approach familiar to urban planners: building up.

Here’s how the strategy is bringing new hope to the technology industry. 

—Sophia Chen

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Anthropic says Alibaba “illicitly” extracted Claude’s capabilities 
It claims the Chinese firm ran a “brazen” campaign to access the model. (BBC)
+ It says it’s the “largest known distillation attack” on the company. (CNBC)
+ The technique trains a weaker model on a stronger one’s outputs. (FT $)
+ Anthropic previously accused other Chinese rivals of using it. (CNN)
+ But it’s still feuding with the White House. (MIT Technology Review)

2 NASA has detected possible chemical signatures of ancient life on Mars
The Perseverance rover spotted complex carbon on rocks. (New Scientist $)
+ The molecules are typically associated with dead organisms. (Guardian)
+ The US has lost its lead in the hunt for alien life. (MIT Technology Review)

3 The EU has joined a US pact to stop relying on Chinese AI
Much of the rest of the world seems to still be a battleground for control. (FT $)
+ China is expanding its AI push in the Global South to counter the US. (The Wire China)
+ Chinese AI experts are freaking out about the AI arms race. (Wired $)

4 OpenAI and Broadcom have unveiled their first jointly designed AI chip
Jalapeño is built to power large-scale AI systems like ChatGPT. (NYT $)
+ It’s part of OpenAI’s push to “build the full stack.” (CNBC)

5 A new report shows ICE has built a vast hi-tech surveillance system
It includes facial recognition, drones, and data scraping.(Guardian)
+ Is the Pentagon allowed to surveil citizens with AI? (MIT Technology Review)

6 Electronics can now be printed onto living tissue
Which could enable smart implants and ingestible diagnostics. (The Economist $)

7 The data center boom is sparking a third wave of inflation 
Demand for memory chips is pushing prices higher.(WSJ $)

8 Companies are scrambling to curb spending on AI token “chewing”
Accenture data shows non-technical staff are draining budgets. (404 Media)

9 Claude Design is creating a bland wave of website uniformity
The AI tool is homogenizing the internet’s aesthetic. (The New Yorker $)

10 Elon Musk has lost his trillionaire status
Thanks to SpaceX stock coming back to Earth. (Business Insider)

Quote of the day

“Tom Brown is not being a weirdo like Dario and can actually engage.” 

—A person directly familiar with calls between the Trump administration and Anthropic tells Wired that they’ve improved since cofounder Tom Brown replaced CEO Dario Amodei in the talks.

One More Thing

TONY LUONG


The quest to learn if our brain’s mutations affect mental health

For years, scientists searching for the roots of conditions like schizophrenia, autism, and Alzheimer’s have focused on single genes. But the real source may lie in a more complex genetic puzzle inside the brain.

Mike McConnell has spent decades exploring the idea that neurons do not all share identical DNA, and that these differences could help explain psychiatric disease. His work has contributed to evidence that brain cells can form a “genetic mosaic,” with mutations that vary across the brain.

Discover how this could reshape our understanding of mental illness.

—Roxanne Khamsi

We can still have nice things

A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)

+ This classical reimagining of the Super Mario soundtrack is exquisite.
+ At long last, we can calculate the fuel efficiency of launching our enemies into the Sun.
+ Before CGI, explosions were an art form. This compilation of classic practical effects is pure action-movie nostalgia.
+ Cambridge botanists lovingly recreated a 336-year-old garden to honor the “father of natural history.” (Big thanks to reader Peter Ryan for the find!) 

Biological performance evaluation of graphene nanoplatelets for intracranial direct current stimulation

Graphene nanoplatelets (GNPs) offer promising properties for neural interface applications, particularly in intracranial direct current (DC) stimulation, due to their high charge injection capacity, flexibility, and biocompatibility. In this study, we comprehensively evaluate the biological and functional performance of GNP-based electrodes for acute and chronic cortical stimulation and recording. GNP electrodes were fabricated via screen-printing on flexible polyimide substrates. They were assessed for cytotoxicity using RAW 264.7 macrophage cell lines and primary hippocampal cultures, showing no evidence of cell death or toxicity. Long-term implantation in non-human primates (50 days) revealed no signs of infection, inflammation, or cortical damage, supporting the biostability of the material. Magnetic resonance imaging confirmed that GNPs produce no imaging artifacts, affirming their compatibility with standard neuroimaging protocols. Functionally, epidural DC stimulation using GNP electrodes modulated neuronal firing rates in the auditory cortex in a polarity-dependent manner, consistent with classical effects of DC stimulation. Furthermore, the same electrodes reliably recorded auditory-evoked potentials, demonstrating dual functionality for stimulation and recording. These findings position screen-printed GNP electrodes as safe, versatile, and effective tools for neurophysiological applications, and highlight their potential for future use in translational neuroscience and neurotherapeutic settings.

Impaired task-dependent cerebral cortex oxygenation in Glut1 deficiency

IntroductionNeuronal activation increases regional glucose utilization and requires coordinated increases in tissue oxygenation. While glucose uptake is regulated by cell type-specific transporter expression, oxygen diffuses more broadly across brain tissue, linking cerebral blood flow to measurable changes in oxygenation using functional near-infrared spectroscopy (fNIRS). In glucose transporter type 1 deficiency (G1D), reduced brain glucose and glycogen levels suggest limited substrate availability to support neural activity.MethodsIndividuals with G1D and age-matched controls underwent fNIRS while performing standardized cognitive tasks. Task-evoked changes in oxygenated and deoxygenated hemoglobin were recorded to quantify cortical activation and regional oxygenation responses.ResultsWe hypothesized that task-dependent metabolic responses are constrained in G1D. Consistent with this hypothesis, fNIRS measurements demonstrated reduced cortical oxygenation responses in individuals with G1D compared with controls.DiscussionThese findings support an altered neuroenergetic response to neural activation in G1D, in which cognitive performance is preserved despite limited substrate availability and attenuated oxygenation responses, consistent with adaptive or compensatory mechanisms.

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling

Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04481-9

Mass-spectrometry-based metabolomic analysis of plasma samples from multiple cohorts of patients treated with immunotherapy across five distinct tumor types, followed by machine learning enabled identification of metabolic signatures, as well as functional exploration, reveals association of increased plasma histidine levels with prolonged survival and its potential for therapeutic intervention.

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial

Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04453-z

In the randomized phase 2 Neo-CheckRay trial, patients with early-stage ER+HER2− breast cancer received neoadjuvant immune-modulating stereotactic body radiation therapy with or without durvalumab, and with or without the anti-CD73 antibody oleclumab, leading to encouraging clinical responses when durvalumab was added including in patients with PD-L1-negative tumors.

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Nature Medicine, Published online: 25 June 2026; doi:10.1038/s41591-026-04471-x

In the ongoing phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5) trial in patients with transplant-eligible, newly diagnosed multiple myeloma, induction with the BCMA×CD3 bispecific engager teclistamab in combination with daratumumab plus lenalidomide, with or without bortezomib, had a similar toxicity profile to other bispecific regimens with an encouraging and deep response rate.

DBS: from neuromodulation to neuroremodelling

Nature Neuroscience, Published online: 25 June 2026; doi:10.1038/s41593-026-02347-4

Deep-brain stimulation (DBS) treats movement and neuropsychiatric disorders through mechanisms that remain unclear. Two studies that combine longitudinal neuroimaging, stimulation experiments and tissue-level analysis show that the effects of DBS evolve in space and time, demonstrating acute effects on network activity as well as providing insights into chronic effects that reshape the networks it engages.